Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4196 trials
Conditions Breast Cancer
Phase PHASE3
Enrollment 180
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

Prospective, multi-center, randomized, open label comparative Phase III study in patients with intermediate to high-risk (as defined in the SURVIVE trial) HER2-positive or HER2-low early breast cancer, who participate in the SURVIVE trial and experience a molecular relapse, as assessed based on a positive circulating tumor DNA (ctDNA) result, with 2:1 allocation to: * Arm A: Trastuzumab-Deruxtecan (i.v. 5,4 mg/kg, q3w) + endocrine therapy (if hormonal-receptor-positive) for 16 cycles or until relapse, if earlier * Arm B: Continuous treatment of physician's choice (may include endocrine treatment, CDK4/6-Inhibition, T-DM1, Olaparib, Trastuzumab, Pertuzumab, Capecitabine or Neratinib)

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Trastuzumab-Deruxtecan — Trastuzumab-Deruxtecan (i.v. 5,4 mg/kg, q3w) + endocrine therapy (if hormonal-receptor-positive) for 16 cycles or until relapse, if earlier
  • Other: Physicians Choice (PhC). — Continuous treatment of physician's choice (may include endocrine treatment, CDK4/6-Inhibition, T-DM1, Olaparib, Trastuzumab, Pertuzumab, Capecitabine or Neratinib)

Primary Outcomes

  • ctDNA clearance rate 12 months after randomization (from enrollment to end of treatment after 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-04-22
Completion: 2032-04-22
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 180 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Prof. Wolfgang Janni
Contact Information
Study Contact:
Wolfgang Janni, Prof. Dr. med.
+49731 500 58536
studienzentrale.ufk@uniklinik-ulm.de
Kerstin Pfister, Dr.
+4973150058536
heroes.studie@uniklinik-ulm.de
University Clinic Ulm
Forca Mehmeti, M.Sc.
073150058536
forca.mehmeti@uniklinik-ulm.de
University Clinic Ulm
Interventions
  • Drug: Trastuzumab-Deruxtecan — Trastuzumab-Deruxtecan (i.v. 5,4 mg/kg, q3w) + endocrine therapy (if hormonal-receptor-positive) for 16 cycles or until relapse, if earlier
  • Other: Physicians Choice (PhC). — Continuous treatment of physician's choice (may include endocrine treatment, CDK4/6-Inhibition, T-DM1, Olaparib, Trastuzumab, Pertuzumab, Capecitabine or Neratinib)
Study Locations (1 sites)
University Clinic Ulm, Ulm, 89075 Germany
Eligibility Criteria
Inclusion Criteria: Patients will be eligible for study participation if they comply with the following criteria: 1. Written informed consent for all study procedures according to local regulatory requirements prior to beginning specific protocol procedures. 2. Females or males, ≥ 18 years and ≤ 75 years of age. 3. Invasive breast carcinoma as revealed by local pathology that is either: 1. HER2-positive defined as an immunohistochemistry (IHC) score of 3+ and/or positive by in situ hybridization (ISH) in Her2 2+ tumors (as defined in 2018 American Society of Clinical Oncology - College of American Pathologists \[ASCO-CAP\] guidelines) 2. HER2-low defined as an immunohistochemistry (IHC) score of 1+ or an IHC score of 2+ with a mandatory negative in situ hybridization (ISH), as defined in 2018 American Society of Clinical Oncology - College of American Pathologists \[ASCO-CAP\] guidelines. 4. Complete resection of the tumor with resection margins free of invasive carcinoma (R0). 5. Participation in the SURVIVE study and evidence of molecular relapse (as assessed based on a positive ctDNA result obtained in the SURVIVE-study) 6. No evidence of metastatic relapse as revealed by a CT-scan (Abdomen/Chest) and a SPECT bone scan that must be performed within 8 weeks before randomization (M0). 7. Completion of surgery, (neo-)adjuvant chemotherapy (if applicable) and radiation therapy (if applicable, whichever occurred last) at least 6 months before randomization. 8. Adjuvant/Postneoadjuvant treatment with Trastuzumab, Pertuzumab, T-DM1, Capecitabine, Pembrolizumab, and Olaparib must be discontinued upon randomization into Arm A (treatment with trastuzumab deruxtecan). The washout periods (see Table 2) must be complied with. Endocrine therapy (i.e. Tamoxifen, Letrozol, Anastrozol, Fulvestrant or Exemestane) can be administered simultaneously to treatment with trastuzumab deruxtecan. 9. Known HR status, per local laboratory assessment, as defined by ASCO-CAP guidelines (≥1%): HR-positive status defined by either positive estrogen receptor (ER) and/or positive progesterone receptor (PR) status. HR-negative status defined by both known negative ER and known negative PR 10. Left ventricular ejection fraction (LVEF) ≥50% within 28 days prior to randomization 11. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 at Screening 12. Adequate organ and bone marrow function within 28 days before randomization as described in table 1. Organ and bone marrow function criteria must also be met when laboratory tests are repeated within 3 days before Cycle 1 Day 1. Transfusion (red blood cell or platelet) or G-CSF administration is not allowed within 2 weeks prior to the day on which marrow function is assessed. 13. Adequate treatment washout period before treatment with trastuzumab deruxtecan (in case of randomization into cohort A), defined in table 2. 14. Female subjects: Evidence of post-menopausal status or negative serum pregnancy test for females of childbearing potential who are sexually active with a non-sterilized male partner. For women of childbearing potential, a negative result for serum pregnancy test (test must have a sensitivity of at least 25 mIU/mL) must be available at the screening visit and urine beta-human chorionic gonadotropin (β-HCG) pregnancy test prior to each administration of Investigational Medicinal Product (IMP). 1. Women of childbearing potential are defined as those who are not surgically sterile (underwent bilateral salpingectomy, bilateral oophorectomy, or complete hysterectomy) or post-menopausal. Women will be considered post-menopausal if they have been amenorrhoeic for 12 months without an alternative medical cause. 2. Female patients of childbearing potential who are sexually active with a non-sterilized male partner must use at least one highly effective method of contraception (see 5.5.1.) from the time of screening and must agree to continue using such precautions for 7 months after the last dose of IMP. Not all methods of contraception are highly effective. Female patients must refrain from breastfeeding while on study and for 7 months after the last dose of IMP. Complete heterosexual abstinence for the duration of the study and drug washout period is an acceptable contraceptive method if it is line with the patient's usual lifestyle (consideration must be made to the duration of the clinical trial); however, periodic or occasional abstinence, the rhythm method, and the withdrawal method are not acceptable. 3. Female subjects must not donate, or retrieve for their own use, ova from the time of randomization and throughout the study treatment period, and for at least 7 months after the final study drug administration. They should refrain from breastfeeding throughout this time. Preservation of ova may be considered prior to enrollment in this study. 15. Male subjects: Non-sterilized male patients who are sexually active with a female partner of childbearing potential must use a condom with spermicide from screening to 4 months after the final dose of IMP. Complete heterosexual abstinence for the duration of the study and drug washout period is an acceptable contraceptive method if it is in line with the patient's usual lifestyle (consideration must be made to the duration of the clinical trial); however, periodic or occasional abstinence, the rhythm method, and the withdrawal method are not acceptable. It is strongly recommended for the female partners of a male patient to also use at least one highly effective method of contraception throughout this period, as described in section 5.5.1. In addition, male patients should refrain from fathering a child, or freezing or donating sperm from the time of randomization/enrolment, throughout the study and for 4 months after the last dose of IMP. Preservation of sperm should be considered prior to enrolment in this study. Exclusion Criteria: 1. Stage IV (metastatic) breast cancer. 2. Patients with a history of any secondary primary malignancy are ineligible with the following exceptions: * ipsi- or contralateral non-invasive carcinoma of the breast (DCIS) * other, curatively treated in-situ disease * adequately treated non-melanoma carcinoma of the skin 3. Prior treatment with T-DXd. 4. Combination of T-DXd with any other anti-cancer treatment is not permitted, except for endocrine therapy. 5. Has substance abuse or any other medical conditions such as clinically significant cardiac or psychological conditions, that may, in the opinion of the investigator, interfere with the subject's participation in the clinical study or evaluation of the clinical study results. 6. Patients with a medical history of myocardial infarction (MI) within 6 months before first exposure to study intervention, symptomatic congestive heart failure (CHF) (New York Heart Association Class II to IV), Subjects with troponin levels above ULN at screening (as defined by the manufacturer), and without any myocardial related symptoms, should have a cardiologic consultation before enrollment to rule out MI. 7. Corrected QT interval (QTcF) prolongation to \> 470 msec (females) or \> 450 msec (males) based on average of the screening triplicate 12-lead ECG. 8. History of (non-infectious) Interstitial lung disease (ILD) / pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening. 9. Uncontrolled infection requiring IV antibiotics, antivirals, or antifungals 10. Active primary immunodeficiency, known uncontrolled active HIV infection or active hepatitis B or C infection. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA. Subjects should be tested for HIV prior to randomization/enrolment if required by local regulations or institutional review board (IRB)/ethics committee (EC). 11. Lung criteria: 1. Lung-specific
Conditions Head and Neck Squamous Cell Carcinoma (H...
Phase PHASE1, PHASE2
Enrollment 27
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

This is a First In Human (FIH), multicenter, open-label, Phase I/II study to evaluate safety, tolerability, Pharmacokinetics (PK), pharmacodynamics, and efficacy of MT-4561 in patients with advanced solid tumors. This study will be conducted in 3 parts. Part 1 is aimed at evaluating safety, tolerability, PK and pharmacodynamics of MT-4561 and determining the Maximum Tolerated Dose (MTD) using the Bayesian Optimal Interval (BOIN) design. The study details and doses of Part 2 (dose-optimization) and Part 3 (Drug-Drug Interaction) will be available after review of applicable Part 1 results.

Design

Study type: Interventional Phases: Phase1, Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: MT-4561 — i.v.

Primary Outcomes

  • Incidence of Adverse Event, Dose limiting toxicities (DLTs) (a 28-day cycle)
  • Number of Patients with Adverse events (AEs) (Screening through 30 days after last dose)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1, PHASE2
Status: Recruiting
Start Date: 2025-04-18
Completion: 2028-08
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 27 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Tanabe Pharma America, Inc.
Principal Investigators:
  • Head of Medical Science (STUDY_DIRECTOR) - Tanabe Pharma America, Inc.
Contact Information
Study Contact:
Clinical Trials Information Desk, to prevent miscommunication,
Please E-mail
information.US@mb.tanabe-pharma.com
Interventions
  • Drug: MT-4561 — i.v.
Study Locations (6 sites)
University of Southern California, Los Angeles, California 90033 United States
START Midwest, Grand Rapids, Michigan 49546 United States
The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive Cancer Center, Columbus, Ohio 43210 United States
The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 United States
National Cancer Center Hospital, Chuo-Ku, Tokyo 104-0045 Japan
National Cancer Center Hospital East, City, Japan
Eligibility Criteria
Main Inclusion Criteria: Patients who have failed at least 1 prior therapy and, who have no standard treatment options demonstrated to provide clinical benefit or who are intolerable to or refuse further standard therapies will be enrolled. * Male or female patient aged 18 years or older at the time of signing the informed consent form * ≥ 1 measurable lesion by the RECIST v1.1 * Eastern Cooperative Oncology Group (ECOG) performance status: 0 to 1 * Life expectancy of at least 3 months * Adequate bone marrow function * Adequate hepatic function * Adequate renal function estimated creatinine clearance ≥ 60 mL/min calculated using the Cockcroft and Gault equation or by institutional method * Part 1: Patients must have a confirmed histologic or cytologic diagnosis of one of the following solid tumors for participation in the study: head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), esophageal cancer, gastric cancer, biliary tract cancer, pancreatic ductal adenocarcinoma (PDAC), breast cancer, ovarian cancer, cervical cancer, endometrial cancer, prostate cancer, urothelial carcinoma, neuroendocrine tumor (NET) or neuroendocrine carcinoma (NEC), soft tissue sarcoma, and NUT carcinoma. Main Exclusion Criteria: * Patients with active brain or leptomeningeal metastases * Any unresolved toxicity ≥ Grade 2 from previous anticancer therapy except for alopecia * Prior systemic anticancer therapy within 4 weeks before first dose of investigational medicinal product (IMP) or 5 half-lives, whichever is shorter, and prior radiotherapy within 2 weeks before first dose of IMP * History of congenital long QT syndrome or clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation or Torsades de pointes) * Patients who received drugs with a known risk of QT interval prolongation or Torsades de pointes within 14 days or 5 half-lives, whichever is shorter, before the start of IMP administration * QT interval corrected for heart rate using Fridericia's correction (QTcF) \> 470 msec at screening
Conditions Breast Cancer Stage IV, Oligometastatic ...
Phase PHASE3
Enrollment 345
Locations 19 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

TAORMINA is an international, multicentre, randomised phase 3 trial for patients with oligometastatic breast cancer (OMBC) that will be allocated to combined stereotactic ablative radiotherapy (SABR) + systemic therapy (investigational arm) versus systemic therapy alone (control arm) as 1st line therapy.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Radiation: SABR — Stereotactic Ablative Radiotherapy is delivered to all metastatic lesions.

Primary Outcomes

  • Progression-free survival (PFS) (3 years after the last patient inclusion)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2022-09-19
Completion: 2030-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 345 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Vastra Gotaland Region
Collaborators: Sahlgrenska University Hospital, Azienda Ospedaliero-Universitaria Careggi, Region Örebro County, Skane University Hospital, Karolinska University Hospital, University Hospital, Umeå, Oslo University Hospital, St. Olavs Hospital, Haukeland University Hospital, University Hospital of North Norway, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Humanitas Research Hospital IRCCS, Rozzano-Milan, Cork University Hospital, St. James's Hospital, Ireland, Beaumont Hospital, Bon Secours Cork Cancer Centre, University College Hospital Galway, Institute of Oncology Ljubljana, Sheba Medical Center
Principal Investigators:
  • Barbro K Linderholm, MD, PhD (PRINCIPAL_INVESTIGATOR) - Sahlgrenska University Hospital, Gothenburg
Contact Information
Study Contact:
Katarzyna Kulbacka-Ortiz, CTO
+46721470685
katarzyna.kulbacka-ortiz@vgregion.se
Annika Baan
+46700906097
annika.baan@vgregion.se
Ella O'Sullivan, MD
+353 (0) 21 4922000
ella.osullivan@hse.ie
Cork University Hospital
Interventions
  • Radiation: SABR — Stereotactic Ablative Radiotherapy is delivered to all metastatic lesions.
Study Locations (19 sites)
Cork University Hospital, Cork, T12 DC4A Ireland
Bon Secours Cork In Partnership with UPMC Hillman Cancer Centre, Cork, T12 DV56 Ireland
St Luke's Radiation Oncology Network (SLRON) at St Luke's Hospital Dublin, St James Hospital Dublin and Beaumont Hospital Dublin, Dublin, Ireland
University Hospital Galway (UHG), Galway, H91 YR71 Ireland
Sheba Medical Center Institute of Oncology, Tel Aviv, 5265601 Israel
Azienda Ospedaliero - Universitaria Careggi, Florence, 3 50134 Italy
Humanitas Cancer Centre, Milan, Italy
Istituto Nationale Tumori (INT), Milan, Italy
Haukeland University Hospital, Bergen, 5021 Norway
Oslo University Hospital, Radiumhospitalet, Oslo, 0424 Norway
Eligibility Criteria
Inclusion Criteria: 1. Histologically or cytological confirmed recurrent OMBC. 2. Age ≥18 years old. 3. OMBC defined as 1-5 metastases in a maximum of two organs confirmed by PET-CT. 4. Patients already on 1st line systemic treatment can be enrolled if repeated tumour evaluations show stable disease. 5. Patients with de novo stage IV OMBC must have a controlled primary tumour regardless of primary surgery or primary systemic treatment. 6. Patients with local recurrence and OMBC must have a controlled local recurrence. 7. ECOG/WHO 0-2. 8. Life expectancy \> 6 months. 9. Known ER, PgR and HER2 status of either primary tumour or metastasis (preferred). 10. Symptomatic bone metastases are allowed if ablative therapy can be delivered. 11. Adequate organ function for the planned treatment according to local guide-lines. 12. For patients with liver metastasis: * No cirrhosis or hepatitis * Hepatic function: * Total bilirubin level \< 3.0 x institutional ULN * ALT, AST, GGT, and alkaline phosphatase levels \< 3.0 x institutional ULN * Albumin \> 2.5 mg/dL * Metastasis not adjutant to stomach or small bowel. 13. For patients with abdominal metastases: adequate renal function with a calculated creatinine clearance of \> 60mL/min. 14. Toxicities from previous adjuvant therapies (excluding alopecia) must have recovered to grade 1 (defined by CTCAE 5.0). Stable grade 2 peripheral neuropathy are considered individually by the investigator. 15. Negative pregnancy test within 14 days prior to start of treatment\*. 16. If childbearing potential, willing to use an effective form of contraception\*. 17. No other malignancy during the last 5 years except for radically treated basal or squamous cell carcinoma of the skin or CIS of the cervix. 18. Signed informed consent and willingness to follow the trial procedures. Exclusion Criteria: 1. \> 1 line of systemic treatment for OMBC due to previous progressing disease (previous treatment of isolated local recurrences with a 2nd adjuvant treatment not included). Change due to toxicity allowed. 2. Oligometastases in brain. 3. Malignant pleural effusion or ascites. 4. Metastasis growth that involves \> 3 vertebra and adjacent spinal cord, spine instability or neurological deficit resulting from compression, 25% spinal canal compromise or progressive neurological deficit. 5. Unable to undergo imaging by either CT scan or MRI. 6. Evidence of any other medical conditions (such as psychiatric illness, infectious diseases, neurological conditions, physical examination or laboratory findings) that may interfere with the planned treatment or affect patient compliance. 7. Pregnancy or breast-feeding. 8. Concurrent malignancy requiring therapy (excluding non-invasive carcinoma or carcinoma in situ).
Conditions Triple Negative Breast Cancer (TNBC), El...
Phase PHASE2
Enrollment 55
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

This study tests a new treatment approach for people with early-stage triple negative breast cancer whose tumors have a high number of immune cells, called tumor-infiltrating lymphocytes or TILs, as seen by a pathologist on tissue review. A high TIL count is a sign the cancer may respond especially well to chemotherapy and immunotherapy together, meaning more toxic treatment may not be needed for everyone. All patients with high TILs will receive 12 weeks of chemotherapy (carboplatin and paclitaxel) with the immunotherapy drug pembrolizumab before surgery, without anthracyclines, a class of chemotherapy drugs that is effective but carries risks of heart damage and, rarely, bone marrow disorders or leukemia. Patients with no cancer found at surgery continue on pembrolizumab alone. Those with residual cancer receive anthracycline-based chemotherapy plus pembrolizumab, closer to current standard treatment. The goal is to personalize treatment, sparing anthracyclines for patients likely to do well without them while reserving stronger therapy for those who need it. The main measure of success is the pathologic complete response rate, with cancer-free survival and overall survival also assessed.

Design

Study type: Interventional Phases: Phase2 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Carboplatin — Target AUC 5 every 3 weeks for 12 weeks (depending on response) OR Target AUC 1.5 every week for 12 weeks (depending on response).
  • Drug: Paclitaxcel — 80 mg/m2 every week for 12 weeks.
  • Drug: Pembrolizumab — 200 mg every 3 weeks for 4-6 cycles (depending on response).

Primary Outcomes

  • Rate of pCR in breast and axilla (60 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2027-01-01
Completion: 2034-05-29
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 55 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Medical University of South Carolina
Collaborators: State University of New York - Upstate Medical University
Principal Investigators:
  • Abirami Sivapiragasam, MD (PRINCIPAL_INVESTIGATOR) - Medical University of South Carolina
Contact Information
Study Contact:
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu
Erinn Mcdowell
McDowelE@upstate.edu
SUNY Upstate Medical University
HCC Clinical Trials Office
843-792-9321
hcc-clinical-trials@musc.edu
Medical University of South Carolina Hollings Cancer Center,
Interventions
  • Drug: Carboplatin — Target AUC 5 every 3 weeks for 12 weeks (depending on response) OR Target AUC 1.5 every week for 12 weeks (depending on response).
  • Drug: Paclitaxcel — 80 mg/m2 every week for 12 weeks.
  • Drug: Pembrolizumab — 200 mg every 3 weeks for 4-6 cycles (depending on response).
Study Locations (2 sites)
SUNY Upstate Medical University, Syracuse, New York 13210 United States
Medical University of South Carolina Hollings Cancer Center,, Charleston, South Carolina 29425 United States
Eligibility Criteria
Inclusion Criteria: Pre-Screening Phase: 1. Age ≥ 18 years at the time of informed consent. 2. Ability to understand and willingness to sign a written informed consent document in accordance with institutional and federal guidelines. 3. Histologically confirmed diagnosis of triple-negative breast cancer (TNBC) or hormone receptor-low invasive breast carcinoma, with clinical anatomic Stage II or Stage IIIA/B as defined by the AJCC 8th Edition Anatomic Breast Cancer Staging System. a. Invasive tumor must be estrogen receptor (ER) and/or progesterone receptor (PR) negative or low, defined as ≤10% positive staining by immunohistochemistry (IHC). b. HER2-negative disease, defined in accordance with current ASCO-CAP HER2 testing guidelines. 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. Screening and Treatment Phases: General Eligibility 1. Individuals of childbearing potential must be willing and able to use highly effective contraception from the time of informed consent, throughout study treatment, and for at least 6 months after the last dose of trial therapy. a. NOTE: Highly effective contraception is defined as methods with a failure rate \<1% per year when used consistently and correctly, and include: copper intrauterine device (IUD); bilateral tubal ligation/occlusion or other documented surgical sterilization; vasectomized partner with documented azoospermia, provided this is the sole sexual partner; or true sexual abstinence, defined as complete abstinence from heterosexual intercourse, when this is the participant's usual and preferred lifestyle. Use of hormonal contraceptive methods (including combined oral contraceptives, progestin-only pills, injectables, implants, hormonal IUDs, patches, or vaginal rings) is not permitted during the study and for at least 6 months after the last dose of study treatment. 2. Willingness and ability to comply with all study procedures, including scheduled visits, treatment plans, laboratory tests, and other protocol-specified requirements. 3. Willingness and ability to sign and date written informed consent prior to initiation of any study-specific procedures. Disease Characteristics 4. Breast and axillary imaging (mammogram, ultrasound, or MRI) must have been completed within 45 days prior to registration. 5. Patients with abnormal axillary lymph nodes (identified clinically and/or radiographically) must undergo routine pathological confirmation via image-guided core biopsy or fine needle aspiration. 6. Presence of: 1. Measurable disease in the breast measuring at least 1cm with or without nodal involvement; or 2. Clinical T0 disease with biopsy-proven regional lymph node involvement (cT0N1-2M0), consistent with an overall anatomic stage II-IIIB classification. i. For patients with clinical T0 disease confirmed by mammogram/US and MRI, nodal involvement must be documented by core needle biopsy or fine needle aspiration of an axillary or other regional lymph node demonstrating invasive breast carcinoma prior to initiation of neoadjuvant systemic therapy. ii. Patients must not have undergone prior surgical excision of an invasive breast primary tumor that would account for the T0 designation (i.e., T0 must not be the result of complete prior excision of the primary breast lesion). 7. Patients with multifocal or multicentric disease are allowed if the dominant tumor is confirmed ER and/or PR ≤10%, and HER2-negative. 8. Patients with bilateral breast cancer are eligible if both tumors are HER2-negative. 9. Staging scans (e.g., CT chest/abdomen/pelvis with a nuclear bone scan) must be performed to rule out metastatic disease under any of the following conditions: a. Two or more abnormal axillary lymph nodes on imaging, or b. Clinical suspicion of metastatic disease, or c. At the discretion of the treating physician. Clinical and Laboratory Requirements 10. Peripheral neuropathy must be Grade ≤1 per CTCAE v5.0. 11. Complete history and physical examination performed within 45 days prior to registration. 12. Adequate hematologic and organ function as defined by the following: a. Hematologic i. Hemoglobin ≥9.0 g/dL (without transfusion or erythropoietin support within 14 days prior to testing) ii. Leukocytes ≥3,000/μL iii. Absolute neutrophil count (ANC) ≥1,500/μL iv. Platelet count ≥100,000/μL b. Hepatic i. AST (SGOT) and ALT (SGPT) ≤3 × ULN ii. For participants without a history of Gilbert's syndrome, total bilirubin ≤1.5 × upper limit of normal (ULN) iii. For participants with a history of Gilbert's syndrome, total bilirubin ≤5 × ULN c. Renal i. Serum creatinine ≤1.5 mg/dL or creatinine clearance ≥50 mL/min/1.73 m² by Cockcroft-Gault formula. ii. Note: Patients with creatinine clearance 30-50 mL/min may be enrolled at the discretion of the Principal Investigator, given that paclitaxel is primarily hepatically metabolized and carboplatin dosing can be adjusted to renal function. 13. Cardiac function must be within acceptable limits, as follows: left ventricular ejection fraction (LVEF) ≥50% by a. Echocardiogram (ECHO), or b. Multi-gated acquisition (MUGA) scan. 14. Participants with known human immunodeficiency virus (HIV)-infection must be on effective antiretroviral therapy (ART) at randomization and have an undetectable viral load test on the most recent test results obtained within six (6) months prior to randomization. 15. Participants with evidence of chronic hepatitis B virus (HBV) infection must have an undetectable HBV viral load while on suppressive therapy on the most recent test results obtained within six (6) months prior to randomization, if indicated. a. NOTE: No testing for HBV is required unless mandated by local health authority. 16. Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. Participants currently being treated for HCV infection must have an undetectable HCV viral load test on the most recent test results obtained within six (6) months prior to randomization, if indicated. 1. NOTE: No testing for HCV is required unless mandated by local health authority. Exclusion Criteria: Participants meeting any of the following criteria will be excluded from the study: Pre-Screening Phase: 1\. Presence of tumor-infiltrating lymphocytes (TILs) \<30% based on central pathology review of hematoxylin and eosin (H\&E) stained slides. Screening and Treatment Phases: Disease-Related Exclusions 1. Presence of N3, inflammatory, or metastatic (M1) breast cancer. 2. History of other malignancies within the past 3 years, with the exception of: 1. Adequately treated non-melanoma skin cancer, or 2. Cervical carcinoma in situ, or 3. Other malignancies with a ≥3-year disease-free interval. Prior and Concurrent Therapy 3. Prior systemic therapy, radiation therapy, or definitive surgery for current breast cancer. 4. Prior treatment with immune checkpoint inhibitors, including anti-PD-1, anti-PD-L1, or any other T-cell co-inhibitory or co-stimulatory agents. 5. Use of investigational agents or devices within 28 days prior to registration 6. Participant is planning to participate, currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment. Medical Conditions 7. History of severe (Grade ≥3) allergic reactions or hypersensitivity to study drugs or their components. 8. Uncontrolled diabetes mellitus or hypertension. 9. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy (7-day clearance period for immunosuppressant therapy prior to starting study treatment, if applicable). 10. History of solid organ transplant. 11. Active autoimmune disease requiring systemic treatment within the past 1 year. 12. Recent

PREgnancy and FERtility Registry

NCT02895165
Recruiting
Conditions Breast Neoplasms, Pregnancy, Fertility P...
Phase Not Applicable
Enrollment 1000
Locations 23 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

The PREgnancy and FERtility (PREFER) study is a comprehensive program aiming to optimize care and improve knowledge around the topics of fertility preservation and pregnancy issues in young breast cancer patients. The program was initiated at the National Institute for Cancer Research, IRCCS AOU San Martino - IST in Genova (Liguria Region, Italy) and then it has been spread to other Italian Institutions under the umbrella of the Gruppo Italiano Mammella (GIM) study group. It is composed of two distinctive studies, one assessing fertility (i.e. PREFER-FERTILITY) and the other pregnancy (PREFER-PREGNANCY) issues. Hence, two different study protocols were developed under the umbrella of the PREFER registry. PREFER-FERTILITY aims to obtain and centralize data about the preferences and choices of young cancer patients on the fertility preservation strategies available in Italy. Furthermore, it aims to assess the outcomes of patients undergoing one or more strategies for fertility preservation in terms of success of the techniques (i.e. recovery of ovarian function, number of cryopreserved oocytes, post-treatment pregnancies) and safety (i.e. long-term survival outcomes). PREFER-PREGNANCY has two main objectives: 1) to obtain and centralize data on the management of breast cancer diagnosed during pregnancy, the obstetrical and paediatric care of children born after prior in utero exposure to anticancer treatments, and the long-term survival outcomes of these patients; 2) to obtain and centralize data on the clinical outcomes of breast cancer survivors that achieve a pregnancy after prior diagnosis and treatment of breast cancer.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Rate of patients interested in the available strategies for fertility preservation (15 years)
  • Rate of patients undergoing the different strategies for fertility preservation (15 years)
  • Type of strategies for fertility preservation proposed by oncologists (15 years)
  • Reasons for refusal of the available strategies for fertility preservation (15 years)
  • Type of anticancer therapies administered during pregnancy (15 years)
  • Safety: pregnancy complications (15 years)
  • Safety: incidence of adverse events (15 years)
  • Disease-free survival (15 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2012-11
Completion: 2032-11
Eligibility
Age: 18 Years – 45 Years
Sex: FEMALE
Volunteers: false
Enrollment: 1000 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Collaborators: Clinical Research Technology S.r.l.
Contact Information
Study Contact:
Lucia Del Mastro, MD
+390105558908
lucia.delmastro@hsanmartino.it
Testore
Ospedale Cardinal Massaia
Saverio Cinieri, MD
00390831537219
saverio.cinieri@ieo.it
Presidio Ospedaliero 'Antonio Perrino'
Interventions
N/A
Study Locations (23 sites)
Ospedale Cardinal Massaia, Asti, Asti Italy
Presidio Ospedaliero 'Antonio Perrino', Brindisi, BR 72100 Italy
AOU di Cagliari Strada, Monserrato, Cagliari Italy
Azienda Ospedaliera S. Croce e Carle, Cuneo, CN 12100 Italy
Arcispedale S. Anna - A.O.U. di Ferrara, Cona, FE 44124 Italy
Irccs Aou San Martino - Ist, Genoa, GE 16132 Italy
Ospedale Vito Fazzi, Lecce, LE 73100 Italy
Ospedale Unico Versilia, Lido di Camaiore, LU 55041 Italy
Azienda Ospedaliera Carlo Poma, Mantua, MN 46100 Italy
Ospedale 'Guglielmo da Saliceto', Piacenza, PC 29121 Italy
Eligibility Criteria
Inclusion Criteria: * breast cancer diagnosis * age between18 and 45 years (only for PREFER-FERTILITY) * have not received any radiation or chemotherapy for cancer before enrolment (only for PREFER-FERTILITY) * absence of metastatic disease (only for PREFER-FERTILITY) * diagnosis of breast cancer during pregnancy or within 1 year from the end of pregnancy or pregnancy after prior diagnosis and treatment for breast cancer (only for PREFER-PREGNANCY) * informed consent Exclusion Criteria: * inability to provide written informed consent * stage IV disease at diagnosis (only for PREFER-FERTILITY) * serious psychiatric disorders

ETHAN - ET for Male BC

NCT05501704
Recruiting
Conditions Male Breast Cancer, Hormone Receptor-pos...
Phase PHASE2
Enrollment 60
Locations 9 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

This research study is looking to see how well male breast cancer responds to preoperative treatment with endocrine therapy and which endocrine therapy regimen is the most effective treatment for male breast cancer. The drugs used in this study are: * Tamoxifen * Anastrozole * Degarelix * Abemaciclib

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Tamoxifen — Taken orally
  • Drug: Anastrozole — Taken orally
  • Drug: Degarelix — Subcutaneous (under the skin) injection
  • Drug: Abemaciclib — Taken orally

Primary Outcomes

  • Change in Ki-67 (At the end of the 3-week window period.)
  • RCB index (At time of surgery.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-10-11
Completion: 2036-04-01
Eligibility
Age: 18 Years and older
Sex: MALE
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Jose Pablo Leone
Collaborators: Eli Lilly and Company, Translational Breast Cancer Research Consortium
Principal Investigators:
  • Jose Pablo Leone, MD (PRINCIPAL_INVESTIGATOR) - Dana-Farber Cancer Institute
Contact Information
Study Contact:
Jose Pablo Leone, MD
617-789-2903
josep_leone@dfci.harvard.edu
Clinical Trials Office Breast Cancer
202-444-2223
Georgetown University Medical Center
Elaine Walsh, MD
Georgetown University Medical Center
Interventions
  • Drug: Tamoxifen — Taken orally
  • Drug: Anastrozole — Taken orally
  • Drug: Degarelix — Subcutaneous (under the skin) injection
  • Drug: Abemaciclib — Taken orally
Study Locations (9 sites)
Georgetown University Medical Center, Washington D.C., District of Columbia 20007 United States
Mayo Clinical Hospital Florida, Jacksonville, Florida 32224 United States
Dana Farber Cancer Institute, Boston, Massachusetts 02115 United States
Mayo Clinic, Rochester, Minnesota 55905 United States
UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina 27599 United States
University of Pennsylvania, Abramson Cancer Center, Philadelphia, Pennsylvania 19104 United States
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania 15232 United States
Vanderbilt Cancer Center, Nashville, Tennessee 37232 United States
M. D. Anderson Cancer Center at University of Texas, Houston, Texas 77030-4009 United States
Eligibility Criteria
Inclusion Criteria: * Men aged 18 years or older, with diagnosis of invasive breast cancer who have not undergone surgical resection of the primary tumor and axillary nodes. * Stage I, II, or III per American Joint Committee on Cancer (AJCC) staging 8th edition (112). * Breast cancer must be hormone receptor-positive and HER2-negative according to definition below assessed by local pathology. * Hormone receptor-positive is defined as: positivity for at least one of the hormone receptors (estrogen receptor \[ER\] or progesterone receptor \[PR\]) by IHC. ER and PR assays are considered positive if there are \> 1% positive tumor nuclei in the samples. * HER2-negative is defined per the current American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline (113). * Patients with multifocal or multicentric disease are eligible if the treating investigator has determined the patient should be treated as ER-positive and HER2-negative. * Bilateral breast cancers are allowed if the treating investigator has determined the patient should be treated as ER-positive and HER2-negative. * Patients with a history of ipsilateral or contralateral DCIS or LCIS are eligible. * ECOG performance status ≤ 2. * Required laboratory values demonstrating adequate organ function: * ANC ≥ 1000/mm3 * Hemoglobin ≥ 8 g/dl * Platelets ≥ 50,000/mm3 * Serum creatinine ≤ 3.0 x ULN (institutional) * Total bilirubin ≤ 2.0 x ULN (institutional). * AST and ALT ≤ 5.0 x ULN (institutional) * Men with partners of childbearing potential must be willing to use one highly effective form of non-hormonal contraception or two effective forms of non-hormonal contraception by the patient and/or partner and continue its use for the duration of the study treatment and for 6 months after the last dose of study treatment. * Non-English-speaking patients are eligible but will be exempt from patient-completed questionnaires. * Willing and able to sign informed consent. * Willing to undergo breast biopsy after completion of window phase. * Patient is able to swallow oral medications. Exclusion Criteria: * Prior endocrine therapy, chemotherapy, radiation therapy, or investigational therapy for the current breast cancer diagnosis. * Prior endocrine therapy, systemic therapy, radiation therapy, or investigational therapy for any other malignancy within the past 12 months. * Diagnosis of inflammatory breast cancer (T4d). * Other concurrent serious diseases that may interfere with planned treatment, including severe cardiac disease, congestive heart failure (CHF) of New York Heart Association (NYHA) Class III or higher, severe pulmonary conditions/illness, uncontrolled infections. * The patient has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment \[e.g. estimated creatinine clearance \<30ml/min\], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea). * The patient has active systemic bacterial infection (requiring intravenous \[IV\] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C \[for example, hepatitis B surface antigen positive\]. Screening is not required for enrollment. * The patient has a personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest.
Conditions Breast Cancer
Phase PHASE3
Enrollment 400
Locations 433 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to learn about the safety and effects of the study medicine PF-07248144 when given along with fulvestrant for the possible treatment of HR-positive, HER2-negative advanced or metastatic breast cancer. HR-positive breast cancer cells have proteins on their surface called receptors that bind to hormones like estrogen and progesterone (female sex hormones). These hormones can promote the growth of cancer cells. HER2-negative describes cells that have a small amount or none of a protein called HER2 on their surface. In normal cells, HER2 helps control cell growth. Cancer cells that are HER2-negative may grow more slowly and are less likely to recur (come back) or spread to other parts of the body than cancer cells that have a large amount of HER2 on their surface. Advanced cancer is a term that is often used to describe cancer that is unlikely to be cured. Metastatic cancer is the type where the cancer cells spread from one part of the body to another. This study is seeking for participants whose breast cancer has gotten worsen after receiving cyclin dependent kinase (CDK) 4/6 inhibitor-based therapy. Half of participants in this study will receive their usual study treatment, everolimus with endocrine therapy (either exemestane or fulvestrant) for HR-positive/HER2-negative advanced or metastatic breast cancer (A/mBC). The study doctor will discuss which hormone therapy is right for the participant before treatment begins. PF-07248144 is a tablet that will be taken by mouth at home every day in a 28-day cycle. Fulvestrant will be given as two injections (one injection in the buttock) at visits to the study clinic. Everolimus and exemestane are also tablets and will be taken by mouth at home every day in a 28-day cycle. The study will compare the experiences of people receiving PF-07248144 in combination with fulvestrant to those of the people who do not. This will help see if PF-07248144 in combination with fulvestrant is safe and effective.

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: PF-07248144 — KAT6 inhibitor
  • Drug: Fulvestrant — Endocrine therapy
  • Drug: Everolimus — mTOR inhibitor
  • Drug: Exemestane — Endocrine therapy

Primary Outcomes

  • Progression Free Survival (PFS) as determined by blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 (From the date of randomization until disease progression or death due to any cause (up to approximately 2 years))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2025-08-05
Completion: 2030-11-04
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Pfizer
Principal Investigators:
  • Pfizer CT.gov Call Center (STUDY_DIRECTOR) - Pfizer
Contact Information
Study Contact:
Pfizer CT.gov Call Center
1-800-718-1021
ClinicalTrials.gov_Inquiries@pfizer.com
Interventions
  • Drug: PF-07248144 — KAT6 inhibitor
  • Drug: Fulvestrant — Endocrine therapy
  • Drug: Everolimus — mTOR inhibitor
  • Drug: Exemestane — Endocrine therapy
Study Locations (433 sites)
Alaska Oncology and Hematology, LLC, Anchorage, Alaska 99508 United States
Ironwood Cancer & Research Centers, Chandler, Arizona 85224 United States
Banner Gateway Medical Center, Gilbert, Arizona 85234 United States
Banner MD Anderson Cancer Center, Gilbert, Arizona 85234 United States
Ironwood Cancer & Research Centers, Gilbert, Arizona 85297 United States
Ironwood Cancer & Research Centers, Glendale, Arizona 85306 United States
Ironwood Cancer & Research Centers, Goodyear, Arizona 85395 United States
Ironwood Cancer & Research Centers, Mesa, Arizona 85202 United States
Ironwood Cancer & Research Centers, Mesa, Arizona 85206 United States
Ironwood Cancer & Research Centers, Phoenix, Arizona 85028 United States
Eligibility Criteria
Inclusion Criteria: * Confirmed diagnosis of HR-positive HER2-negative breast cancer with evidence of locally advanced or metastatic disease, which is not amenable to surgical resection or radiation therapy with curative intent. * Prior CDK4/6 inhibitor therapy in combination with endocrine therapy in advance metastatic setting or in adjuvant setting with documented progression during or within 12 months after the last dose of CDK4/6i. * Participants are eligible if they previously received CDK4/6i or ET as a monotherapy, or in combination for rechallenge therapy in the advance or metastatic setting; have received prior therapy targeting estrogen receptor 1 (ESR1) or breast cancer gene (BRCA)1/2. * Measurable disease evaluable per Response Evaluation Criterion in Solid Tumors (RECIST) v.1.1 or non-measurable bone-only disease * Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1. Exclusion Criteria: * Documented detectable PIK3CA/AKT1/PTEN alterations in tissue * Received greater than two prior lines of systemic therapy in the advance or metastatic setting * Had received any prior chemotherapy, including antibody drug conjugates (ADCs), in advance or metastatic setting. Participants who have previously received chemotherapy in the (neo)adjuvant setting are not excluded from the study. * Any medical or psychiatric condition that may increase the risk of study participation or make the participant inappropriate for the study. * Renal impairment, hepatic dysfunction, or hematologic abnormalities.
Conditions Breast Carcinoma, Male Breast Carcinoma,...
Phase NA
Enrollment 800
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

This study compares the experiences of people who receive information about genetic testing from a computer-generated character to patients who receive information from a human genetics healthcare provider. Patients with cancer are increasingly recommended for genetic testing as standard of care. Multiple factors contribute to low usage of genetic testing but for many patients the lack of access to genetic counseling and testing is an important and flexible factor. Lack of access is especially relevant to racial/ethnic minority patients and those living in non-metropolitan rural settings who are frequently cared for at safety-net hospitals with limited genetics services. Alternative delivery models are necessary to improve rates of access to genetic testing in patients with cancer. Health information technology is under used by genetics providers. A patient-facing relational agent (PERLA) will provide pre-test genetics education in both English and Spanish across two clinical settings to facilitate more timely access to genetic testing. Using the PERLA intervention may help researchers learn different ways to provide education about genetic testing to patients with cancer compared to usual care.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: None

Interventions / Regimen

  • Other: Best Practice — Receive provider-based genetic counseling
  • Other: Educational Intervention — Receive genetics education
  • Other: Electronic Health Record Review — Ancillary studies
  • Other: Genetic Counseling — Receive provider-based genetic counseling
  • Other: Interview — Ancillary studies
  • Other: Survey Administration — Ancillary studies

Primary Outcomes

  • Proportion of participants who receive genetic testing (Up to 3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2023-10-24
Completion: 2028-10-24
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: true
Enrollment: 800 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Southern California
Collaborators: National Cancer Institute (NCI), Northeastern University, Dana-Farber Cancer Institute
Principal Investigators:
  • Charite Ricker, MS (PRINCIPAL_INVESTIGATOR) - University of Southern California
Contact Information
Study Contact:
Charite Ricker, MS
323-409-7710
ricker@usc.edu
Charite Ricker
323-409-7710
ricker@usc.edu
USC / Norris Comprehensive Cancer Center
Charite Ricker
USC / Norris Comprehensive Cancer Center
Interventions
  • Other: Best Practice — Receive provider-based genetic counseling
  • Other: Educational Intervention — Receive genetics education
  • Other: Electronic Health Record Review — Ancillary studies
  • Other: Genetic Counseling — Receive provider-based genetic counseling
  • Other: Interview — Ancillary studies
Study Locations (2 sites)
USC / Norris Comprehensive Cancer Center, Los Angeles, California 90033 United States
University of Rochester, Rochester, New York 14642 United States
Eligibility Criteria
Inclusion Criteria: * Age \> 18 years old * Diagnosed with least one of the following: * Epithelial ovarian cancer * Exocrine pancreatic cancer * Metastatic or high or very high-risk prostate cancer * Breast cancer at or before age 50 * Bilateral breast cancer * Triple negative breast cancer * Male breast cancer OR * Healthcare provider who treats patients with any of the above types of cancer * Able to read and write in English or Spanish * Able to provide informed consent Exclusion Criteria: * Patients who cannot provide informed consent * Patients who cannot see, read, or write * Patients who have the cancer and clinical characteristics defined in the inclusion criteria, but who do not speak English or Spanish * Patients with none of the listed cancer diagnoses and clinical characteristics * Healthcare provider who do not treats cancer patients
Conditions Type 2 Diabetes
Phase NA
Enrollment 900
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

This randomized controlled trial will assess the impact of the FoodSwitch mobile app, which provides interpretive front-of-pack labelling via barcode scanning, in 900 Swedish adults with type 2 diabetes. Participants will be randomized to app + standard advice or standard advice alone. The primary outcome is change in HbA1c at 6 months; secondary outcomes include anthropometrics, quality of life, medication use, hospitalizations, and mortality.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Other Masking/blinding: Single

Interventions / Regimen

  • Other: FoodSwitch — Access to the 'DiabetesSwitch' filter of the FoodSwitch app when grocery shopping. When a packaged food item bar code is scanned, the FoodSwitch app will show an interpretive nutritional information score for the scanned product and recommend alternate healthier food options in the same category.

Primary Outcomes

  • Mean HbA1c (Change from baseline at week 26)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-08-25
Completion: 2031-12-31
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 900 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Linkoeping University
Principal Investigators:
  • Karin Rådholm, MD, PhD (STUDY_DIRECTOR) - Linkoeping University
Contact Information
Study Contact:
Lana Hebib, MD
013-28 10 00
lana.hebib@liu.se
Siri Fägerstam
+46-(0)13-281661
diatest-help@liu.se
Linköping University
Interventions
  • Other: FoodSwitch — Access to the 'DiabetesSwitch' filter of the FoodSwitch app when grocery shopping. When a packaged food item bar code is scanned, the FoodSwitch app will show an interpretive nutritional information score for the scanned product and recommend alternate healthier food options in the same category.
Study Locations (1 sites)
Linköping University, Linköping, Sweden
Eligibility Criteria
Inclusion criteria: * Age between 18 and 75 years * Self-reported type 2 diabetes with a duration of ≥2 years * Regularly grocery shopping Exclusion criteria: * No access to BankID (a digital identification system commonly used in Sweden) * Failure to complete eligibility screening and run-in periods
Conditions Type 2 Diabetes
Phase NA
Enrollment 75
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if exercise training of high or moderate intensity is most optimal to improve brain health and prevent neurodegeneration in type 2 diabetes patients. The main question it aims to answer is: What is the effect of exercise training of high vs. moderate intensity on brain metabolism, brain perfusion, and cognition in type 2 diabetes? Researchers will compare the exercise training groups to a control group without exercise training to determine the effect of exercise training on the brain in type 2 diabetes. Participants will exercise for 6 months, 3 times per week. Before and after these 6 months, they will undergo: * a brain MRI scan * cognitive tests * blood sampling

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Prevention Masking/blinding: Single

Interventions / Regimen

  • Other: Exercise intervention — The exercise intervention entails 6 months of supervised exercise on a hometrainer at high or moderate intensity, 3 times per week

Primary Outcomes

  • Neurometabolite levels (From enrollment to the end of treatment at 6 months)
  • Changes in arterial spin labelling measured by means of magnetic resonance imaging (MRI) (From enrollment to the end of treatment at 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-11-08
Completion: 2027-08
Eligibility
Age: 30 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 75 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Hasselt University
Collaborators: Universitaire Ziekenhuizen KU Leuven, Jessa Hospital, Research Foundation Flanders
Principal Investigators:
  • Dominique Hansen, Full professor (PRINCIPAL_INVESTIGATOR) - Hasselt University
  • Koen Cuypers, Assistant professor (PRINCIPAL_INVESTIGATOR) - Hasselt University
Contact Information
Study Contact:
Dominique Hansen, Full Professor
+3211292126
dominique.hansen@uhasselt.be
Jitske Vandersmissen, PhD student
+3211268387
jitske.vandersmissen@uhasselt.be
Dominique Hansen, Full professor
+3211292126
dominique.hansen@uhasselt.be
Hasselt University
Interventions
  • Other: Exercise intervention — The exercise intervention entails 6 months of supervised exercise on a hometrainer at high or moderate intensity, 3 times per week
Study Locations (1 sites)
Hasselt University, Hasselt, Limburg 3500 Belgium
Eligibility Criteria
Inclusion Criteria: * type 2 diabetes * no insulin therapy * 30-75 years old * physically inactive Exclusion Criteria: * MRI contraindications * psychological disorders * exogenous insulin therapy * history of coma, transient ischemic attack, head trauma, brain tumor, stroke, epilepsy, and other central nervous system diseases that could cause dementia or presence of dementia before T2DM * suffering from any disease with significant impact on exercise intervention participation such as: chronic heart disease (e.g. valve insufficiency ≥ grade 2) or significant arrhythmias, cardiac events less than one year ago (myocardial infarction, coronary artery bypass graft, percutaneous coronary intervention), clinical heart failure (oedema, shortness of breath), percutaneous coronary intervention less than one year ago, chronic obstructive pulmonary disease (COPD), cerebrovascular or peripheral vascular disease * severe hypertension (\>160/110 mmHg) * ongoing cancer, severe neuropathy (limiting exercise participation) * renal disease (GRF \<45 ml/min/1,73 m2) * inability to regularly participate in the exercise intervention * pregnancy * breastfeeding
Conditions T2DM
Phase EARLY_PHASE1
Enrollment 9
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

Primary Objectives: •To evaluate the safety and tolerability of a single dose of Exenatide Circular RNA-Lipid Nanoparticle Injection(CR059)in Chinese subjects with T2DM. Secondary Objectives: * To characterize the pharmacokinetic (PK) profile of a single dose of Exenatide Circular RNA-Lipid Nanoparticle Injection(CR059) in Chinese subjects with T2DM; * To characterize the pharmacodynamic (PD) profile of a single dose of Exenatide Circular RNA-Lipid Nanoparticle Injection( CR059) in Chinese subjects with T2DM; * To evaluate the immunogenicity of a single dose of Exenatide Circular RNA-Lipid Nanoparticle Injection( CR059) in Chinese subjects with T2DM; Participants : Diagnosed with T2DM for at least 3 months but less than 5 years, according to the Chinese Diabetes Society's diagnostic criteria

Design

Study type: Interventional Phases: Early Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Exenatide Circular RNA-Lipid Nanoparticle Injection( CR059)) — use one dose per person

Primary Outcomes

  • Incidence of Treatment-Emergent Adverse Events (TEAEs) (From the first dosing (Day 1 ) of study drug until completion of the post treatment follow-up visit(Day 36))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: Recruiting
Start Date: 2026-01-20
Completion: 2026-08-31
Eligibility
Age: 18 Years – 65 Years
Sex: ALL
Volunteers: false
Enrollment: 9 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The First Affiliated Hospital of Henan University of Science and Technology
Collaborators: PegBio Co., Ltd.
Contact Information
Study Contact:
Hongwei Jiang, PhD Supervisor
0379-69823582
jianghw@haust.edu.cn
Hongwei Jiang, Professor
0379-69823582
jianghw@haust.edu.cn
The First Affiliated Hospital of Henan University of Science and Technology
Interventions
  • Drug: Exenatide Circular RNA-Lipid Nanoparticle Injection( CR059)) — use one dose per person
Study Locations (1 sites)
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan 310015 China
Eligibility Criteria
Inclusion Criteria: * Chinese male or female, 18≤age≤-65 years . * Diagnosed with T2DM for at least 3 months but less than 5 years, according to the Chinese Diabetes Society's "Chinese Guidelines for the Prevention and Treatment of Type 2 Diabetes (2024 Edition)" diagnostic criteria. * Patients who have failed treatment with diet and exercise alone, or metformin monotherapy, or a stable regimen for 12 weeks of metformin (dose ≥1500 mg/day or maximum tolerated dose ≥1000 mg/day) combined with one of the following oral antidiabetic drugs (or their fixed-dose combinations): sulfonylureas, glinides, alpha-glucosidase inhibitors, SGLT2 inhibitors, or thiazolidinediones (at ≥1/2 the maximum approved dose, or the recommended minimum maintenance dose for SGLT2 inhibitors e.g., empagliflozin 10mg, canagliflozin 100mg). Fasting Plasma Glucose (FPG) must be \<13.0 mmol/L, and 7.5%≤HbA1c ≤ 10.0%. * 18.5 kg/m²≤Body Mass Index (BMI) ≤40.0 kg/m² at screening and enrollment * Subjects have no pregnancy plan from screening until 3 months after the last dose and are willing to use at least one effective method of contraception during the entire trial period until 3 months after the last dose. * Able to understand and willing to sign the informed consent form, and fully understand the trial content, procedures, and potential adverse reactions. * Able to complete the trial according to the protocol requirements. Exclusion Criteria: * Diagnosis of type 1 diabetes, diabetes due to pancreatic injury, or specific types of diabetes due to other diseases (e.g., acromegaly or Cushing's syndrome). * History of acute diabetic complications, such as ketoacidosis or hyperosmolar coma, within 6 months before screening. * Presence of severe chronic diabetic complications (e.g., proliferative diabetic retinopathy, severe diabetic neuropathy, diabetic foot, etc.) within 6 months before screening, deemed by the investigator as unsuitable for participation. * Allergic constitution (allergy to ≥2 types of drugs or foods) or keloid tendency, or clear history of drug allergy, or investigator suspects potential allergy to the investigational product or its components or similar drugs. * Fasting plasma glucose \<3.9 mmol/L at screening or before enrollment, and/or history of ≥2 episodes of severe hypoglycemia or recurrent symptomatic hypoglycemia within 6 months before screening. * History or presence of Cushing's syndrome, polycystic ovary syndrome, or other hereditary endocrine diseases, or obesity secondary to factors such as hormones. * Use of weight-control medications or weight-loss surgery within 3 months before screening, or weight fluctuation exceeding 5% within 3 months. * Clinically significant abnormal TSH, FT3, or FT4 at screening, or previous diagnosis of thyroid dysfunction, deemed unsuitable by the investigator. * Personal or family history of multiple endocrine neoplasia type 2; personal or family history of medullary thyroid carcinoma; or thyroid nodules classified as C-TIRADS category 4 or higher on ultrasound. * History or presence of malignant tumors (except cured basal cell carcinoma or cervical carcinoma in situ). * History of thrombotic diseases (e.g., deep vein thrombosis, pulmonary embolism, stroke), known bleeding diathesis or coagulation dysfunction, major thrombotic event within 6 months, or any coagulation parameter ≥1.5x ULN, or clinically significant abnormal coagulation function deemed unsuitable by the investigator. * Long-term use (over 1 month) or current use of anticoagulants (e.g., warfarin, rivaroxaban, dabigatran) or antiplatelet drugs (e.g., aspirin, clopidogrel) before screening. * Diagnosis of significant cardiovascular or cerebrovascular disease within 6 months before screening, including but not limited to acute stroke, transient ischemic attack (TIA), acute coronary syndrome, coronary heart disease, heart failure, arrhythmia requiring treatment, etc. * History of gout or gout attack within 6 months before screening or before enrollment. * Untreated or poorly controlled hypertension (systolic BP \>160 mmHg and/or diastolic BP \>100 mmHg) at screening or before enrollment. Patients on antihypertensive therapy must have a stable regimen and dose for 1 month. If BP criteria are not met at screening/enrollment, one re-test is allowed. Exclusion if both readings fail. * Heart rate at rest (after at least 10 min) \<50 bpm or \>100 bpm at screening or before enrollment. One re-test is allowed. Exclusion if both readings fail. * PR interval \>210 ms and/or QRS complex duration \>120 ms, and/or QTcF \>450 ms at rest at screening or before enrollment. If criteria not met, repeat ECG twice on the same day; use the average of 3 measurements for judgment. * History of clinically significant chronic or acute exacerbating respiratory diseases, including but not limited to asthma, COPD (excluding obstructive sleep apnea). * History of severe gastrointestinal disease (e.g., active ulcer, gastroparesis, pyloric obstruction, inflammatory bowel disease) within 6 months before screening or before enrollment, or gastrointestinal surgery, or long-term use of drugs directly affecting GI motility due to chronic GI disease, deemed unsuitable by the investigator. * Severe renal disease or estimated Glomerular Filtration Rate (eGFR) \<60 mL/min/1.73m² (CKD-EPI formula) at screening or before enrollment. * Serum amylase or lipase \>3x Upper Limit of Normal (ULN) at screening or before enrollment, or history/known chronic pancreatitis, acute pancreatitis, pancreatic injury. * History of cholelithiasis, acute or chronic cholecystitis (except those with no residual biliary stones post-treatment or post-cholecystectomy without sequelae, deemed eligible by the investigator). * Severe dyslipidemia, with LDL-C ≥4.40 mmol/L or triglycerides (TG) ≥5.65 mmol/L at screening or before enrollment. If on lipid-lowering therapy, regimen and dose must be stable for 1 month. * Clear history of psychiatric disorders (e.g., depression, schizophrenia, bipolar disorder) within 2 years before screening. * Major surgery within 1 month before screening, or presence of severe infection or active inflammation. * History of blood donation \>400 mL, transfusion, or blood loss within 90 days before screening or before enrollment. * Any of the following laboratory abnormalities at screening or before enrollment: 1. ALT or AST \>2x ULN; 2. Total Bilirubin \>1.5x ULN; 3. Calcitonin ≥35 pg/mL; 4. Hemoglobin \<110 g/L (female) or \<120 g/L (male); 5. Clinically significant abnormal platelet count; 6. Clinically significant abnormal white blood cell or neutrophil count; * Use of any approved or unapproved weight-affecting drugs or products within 3 months before screening, including but not limited to orlistat, phentermine-topiramate, naltrexone-bupropion, systemic corticosteroids, antidepressants (SSRIs, SNRIs, tricyclics, tetracyclics), antipsychotics/sedatives (e.g., imipramine, amitriptyline, mirtazapine, paroxetine, phenelzine, chlorpromazine, thioridazine, clozapine, olanzapine, valproic acid, lithium), etc. * Use of any DPP-4 inhibitor, or GLP-1, GIP, GCG receptor agonists, or FGF-21 within 6 months before screening. * History of bariatric surgery (except liposuction/abdominoplasty \>1 year prior). * Participation in any drug or medical device clinical trial within 3 months before screening or before enrollment (except screen failures). * Positive serology for HBsAg, anti-HCV antibody, anti-TP antibody, or anti-HIV antibody at screening. * History of drug abuse and/or alcoholism (weekly alcohol intake \>14 units) within 6 months before screening * Positive urine drug screen or alcohol breath test at screening. * Pregnant or lactating females, or subjects using oral contraceptives. * Intolerance to venipuncture or history of needle syncope, blood-injury syncope. * Any other physiological, psychological, or situational condition deemed by the investigator as unsuitable for trial participation.
Conditions Type 1 Diabetes (T1D), Type 2 Diabetes (...
Phase NA
Enrollment 102
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-11-02
Study Details Design, interventions, and primary outcomes

About This Study

A 13-week multi-center single-arm trial, preceded by a 2-week standard therapy phase, will be conducted to assess the safety of MODI, an insulin titration algorithm, in adults with type 1 diabetes (T1D) who use multiple daily insulin injections (MDI), or with type 2 diabetes (T2D) who use MDI, basal insulin only, or who are candidates to initiate basal insulin, in conjunction with continuous glucose monitoring (CGM).

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Device: MODI Algorithm — All participants use MODI insulin titration algorithm. Includes Diary app used to view treatment plans shared by MODI and manually log events (insulin intake, meal, physical activity and others) by participants; also includes a bolus calculator.

Primary Outcomes

  • CGM-measured percent time <54mg/dL (13 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-05-25
Completion: 2027-01
Eligibility
Age: 18 Years – 80 Years
Sex: ALL
Volunteers: false
Enrollment: 102 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: DreaMed Diabetes
Collaborators: Jaeb Center for Health Research, Abbott Diabetes Care
Contact Information
Study Contact:
Illias Spanakis, MD
410-605-7000
ispanakis@som.umaryland.edu
Baltimore VA Medical Center Univ of Maryland
Davida Kruger
313-916-3906
dkruger1@hfhs.org
Henry Ford Health System
Davida Kruger
Henry Ford Health System
Interventions
  • Device: MODI Algorithm — All participants use MODI insulin titration algorithm. Includes Diary app used to view treatment plans shared by MODI and manually log events (insulin intake, meal, physical activity and others) by participants; also includes a bolus calculator.
Study Locations (6 sites)
Baltimore VA Medical Center Univ of Maryland, Baltimore, Maryland 21201 United States
Henry Ford Health System, Detroit, Michigan 48202 United States
SUNY Upstate Medical Center, Albany, New York 12246 United States
Centricity Research - Morehead City, Morehead City, North Carolina 28557 United States
Texas Diabetes & Endocrinology, Austin, Texas 78731 United States
Diabetes & Endocrine Treatment Specialisits (DETS), Sandy City, Utah 84093 United States
Eligibility Criteria
Inclusion Criteria: 1. Clinical diagnosis, based on investigator assessment, of T1D or T2D of at least 6 months duration at time of informed consent 2. Insulin therapy as follows: 1. If T1D, using MDI insulin therapy for at least 3 months prior to screening; willing to follow a mealtime insulin dosing approach during the study, using either (a) time-of-day-based dosing (breakfast, lunch, dinner) or (b) meal-size-based dosing (small, normal, large); and taking 1 basal insulin injection per day for at least 1 week prior to screening 2. If T2D, either: i. not using insulin in the 3 months prior to screening, but require initiation of a basal-only insulin regimen based on investigator assessment ii. using only basal insulin for at least 3 months prior to screening and taking 1 basal insulin injection per day for at least 1 week prior to screening iii. using MDI for at least 3 months prior to screening; willing to follow a mealtime insulin dosing approach during the study, using either (a) time-of-day-based dosing (breakfast, lunch, dinner) or (b) mealsize-based dosing (small, normal, large); and taking 1 basal insulin injection per day for at least 1 week prior to screening 3. Age at time of consent 18-80 years 4. HbA1c \>7.5% and \<12% as measured by point-of-care device or local lab at the time of screening 5. Using only injected insulin types that are specified in the MODI Instructions for Use materials 6. Stable doses of non-insulin glucose lowering medications over the 4 weeks preceding screening as determined by Investigator and no changes anticipated for the duration of the study, unless a dose reduction or discontinuation, as determined by Investigator, is indicated for safety reasons 7. Stable doses of weight loss medications that may have a meaningful effect on glycemic control over the 4 weeks preceding screening and no changes anticipated for the duration of the study, unless a dose reduction or discontinuation, as determined by Investigator, is indicated for safety reasons 8. Weight between 80 - 440 lb at the time of screening 9. Willing to use FSL 3 System according to manufacturer instructions and to avoid use of any other personal CGM system during the period of study participation 10. Willing to document insulin delivery, meals, and daily activities in the Diary mobile app 11. Has a smartphone compatible with study requirements: either iOS version 17.0 or higher, or Android version 10.0 or higher, and willing to install required apps and use them as instructed during the period of study participation, with internet connectivity for a data upload at least once per day. 12. Is deemed an appropriate candidate for automatic insulin guidance therapy per Investigator assessment 13. Investigator has confidence that the participant has the cognitive ability necessary for study participation, can successfully operate all study devices, and can adhere to the protocol 14. Has a sufficient understanding of written/spoken English for legally effective informed consent and successful use of the study mobile apps 15. If woman of childbearing potential, is willing and able to have pregnancy testing Exclusion Criteria: 1. Use of an insulin pump within 3 months prior to informed consent 2. Use of mixed insulin or intermediate insulin (NPH) within the past 3 months prior to screening 3. Taking more than 128 units of daily basal insulin or more than 79 units in a single bolus insulin injection in the 7 days prior to screening 4. Any medical condition which in the opinion of the investigator, would put the participant at an unacceptable safety risk, such as untreated malignancy, unstable cardiac disease, unstable or end-stage renal disease, and/or eating disorders (i.e. anorexia/bulimia) 5. Current or known history of coronary artery disease that is not stable with medical management, including unstable angina, or angina that prevents moderate exercise despite medical management, or a history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting within the 12 months prior to screening 6. Any planned surgery during the study which could be considered major in the judgment of the investigator 7. History of more than 1 severe hypoglycemic event in the 6 months prior to screening 8. History of diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic syndrome (HHS) in the 6 months prior to screening 9. Blood disorder or dyscrasia within 3 months prior to screening which in the investigator's opinion could interfere with determination of HbA1c 10. Any condition or intervention that may affect red blood cell turnover, in the 3 months prior to the study and during the study, such as blood transfusion or donation 11. Has taken oral or injectable corticosteroids within 2 weeks prior to screening or plans to take oral or injectable corticosteroids during the study 12. Unable to follow clinical protocol for the duration of the study or is otherwise deemed unacceptable to participate in the study per the Investigator's clinical judgment 13. Is an employee of DreaMed Diabetes, is a study Investigator or a member of the Investigator's study team, or is immediate family member (spouse, biological or legal guardian, child, sibling, parent) of any of the aforementioned 14. Participation in another clinical study using an investigational drug or device in the 90 days prior to screening or intends to participate during the study period 15. Pregnant or lactating, planning to become pregnant during the study, or is a woman of childbearing potential and not on acceptable form of birth control (acceptable includes abstinence, condoms, oral/injectable contraceptives, IUD, or implant); childbearing potential means that menstruation has started, and the participant is not surgically sterile or greater than 12 months postmenopausal) 16. Unable to tolerate adhesive tape or has any unresolved skin condition that could impact the CGM sensor